Article · 5 min read
Sessions 2026 is the first under new American Heart Association president Manesh Patel, a Duke cardiologist who came up through clinical trials. Expect a podium that rewards hard endpoints, and an exhibit hall where trial-site consolidation is quietly rewriting who controls enrollment.
AHA Scientific Sessions runs November 6 to 9 at McCormick Place in Chicago, roughly 17,000 registered cardiologists, trialists, and pharma and device teams under one roof, the largest cardiovascular science meeting on the calendar. It opens this year under a new American Heart Association president, Duke cardiologist Manesh Patel, and that changes what gets rewarded from the podium.
Cardiovascular Business reported it about four weeks before this brief: Duke's Manesh Patel is the 2026-27 AHA president. Sessions 2026 is his first as the association's public face, and the president sets the emphasis.
Patel is a working cardiologist. His public record runs through clinical trials, the anticoagulation and interventional work where a mechanism only counts once a hard endpoint moves. So watch the late-breakers. A room led by a trialist tends to reward the readouts that survive scrutiny over the ones that photograph well for a press release.
There's a second signal in the AHA's own newsroom. The association just put $3.4 million into cardiac arrest detection and recovery research, funding groups in New York and Oregon. That's a resuscitation-science bet, and it lines up with a president who thinks in endpoints and enrollment. Read the two together and the 2026 story is about rigor, not spectacle.
That's the section to screenshot before you build your schedule.
Straight from the bundle: AHA hasn't posted a public speaker or session list, and there were no named speakers to research. So this is roles to watch, not names to quote.
The opening president's address. Patel's first. The question isn't ceremonial. Does he name a specific priority, trial integrity, endpoint standards, enrollment diversity, or keep it to the usual heart-health lines? Whatever he names is what AHA funds and platforms for the next year.
The Late-Breaking Clinical Trials blocks. This is the reason the meeting exists. One to pre-flag: Nature published the POLY-HF randomized trial four weeks before this brief, a polypill for heart failure with reduced ejection fraction. A fixed-dose HFrEF combination is exactly the kind of result that lands at AHA. If it presents, ask the PI the real one. Did the polypill actually raise guideline-directed therapy adherence, or just shrink the pill count without moving outcomes?
The resuscitation-science sessions. Follow the $3.4 million. Find the New York and Oregon cardiac-arrest groups AHA just funded and ask what gap the money is chasing, detection, field treatment, or recovery. Their answer tells you where the next AHA and NIH grant cycles point.
The structural-heart and electrophysiology interventional sessions. Where device money and procedural volume meet. Ask any panelist which of their late-breakers changes Monday-morning practice and which is a line extension dressed as news.
Skip a plenary for these if you have to.
Trial-site economics. Not a labeled session, but corner anyone from the site-network world in the hallways. Iterative Health just bought cardiology sites from NextStage Clinical Research and raised $77 million to expand into cardiology and obesity. Who owns trial-site capacity is the most underpriced story in cardiovascular research right now.
Guideline statement sessions. Boring room, highest stakes in the building. This is where AHA moves an actual practice recommendation, and one line change ripples into millions of prescriptions. If you sell a drug or device with a guideline stake, this room is your whole trip.
Fixed-dose combination and polypill methodology. POLY-HF makes it timely. The live debate is reimbursement, whether payers cover a combination pill at a price that clears the component generics. Sit in on the health-economics framing. That's where the commercial fate gets decided.
International and Asia-Pacific medtech. Bain flagged APAC as the next medtech export engine. The partner-country sessions are where you find out whether that's a slide or a supply chain. Under-attended, over-informative.
No official sponsor list in the bundle, so these come from the last 90 days of sector news, not a floor map. Four worth your walk-through.
Milestone Pharmaceuticals. What they'll say: CARDEMYST, their newly approved therapy that began commercial sales in the first quarter of 2026, is live. What they're actually selling: their first real revenue. A single-product small-cap at its commercial debut lives and dies on prescriber uptake and payer coverage, so the booth pitch is about getting cardiologists to write it. Ask about formulary wins, not mechanism.
Iterative Health. What they'll say: clinical-research technology for faster trials. What they're actually selling: control of trial-site capacity. The $77 million raise and the NextStage cardiology-site purchase mean they're becoming the landlord that pharma sponsors rent patients from. If you run trials, they want your enrollment budget. If you're a cardiologist, they want your site.
Rocket Pharmaceuticals. What they'll say: a genetic-medicine pipeline. What they're actually doing: managing runway. They sold a rare-pediatric-disease priority review voucher for $180 million in mid-2026. That's a financing move. It funds the pipeline and says nothing about how the pipeline is reading out, so treat their booth energy as a tell on cash, not on data.
CorDynamics. What they'll say: cardiovascular contract research. What they're actually selling: outsourced early-stage capacity to sponsors who've cut internal preclinical headcount. They announced their Chicago presence early, and a CRO doesn't come to McCormick Place for badge scans. They're hunting business-development conversations.
Three fights you'll hear in the hallway and the coffee line.
One. Whether the HFrEF polypill is a genuine adherence fix or a reimbursement headache. POLY-HF looks good on paper. The floor argument is whether payers cover a fixed-dose combination priced above its generic parts, because a pill nobody reimburses helps nobody.
Two. Whether trial-site consolidation speeds enrollment or quietly narrows who ends up in cardiology trials. Concentrate sites under a few venture-backed networks and you get faster starts and thinner geographic and demographic spread. The generalizability crowd will push back hard.
Three. Whether Patel's rigor emphasis actually reshapes the late-breaker mix or gets swamped by the surrogate-endpoint readouts that move share prices. Presidents set tone. Markets set incentives. Those two don't always pull the same direction.
One thing the podium won't say out loud: the sponsors in that exhibit hall are slowly losing their grip on trial enrollment. When a venture-backed network owns the cardiology sites, the pharma company walks in as a tenant, renting access to patients it used to own the relationship with. Everybody at the booths knows it. Nobody says it into a microphone, because the people who'd have to admit it are the ones whose position is eroding.
You'll leave Chicago with a full badge-scan export and a jacket pocket of cards from the handful who actually matter, the trialist you cornered after the late-breaker, the medical-affairs lead whose therapy maps to yours. The bundle's own note on this audience is blunt: KOL outreach has a tight post-show window. It's true. By the Monday you're back at your desk, half those warm contacts have cooled, and the follow-up you meant to send is competing with two hundred others just like it.
Met sorts that stack while you still remember which conversation was which. It ranks the cards worth a real follow-up above the ones you scanned out of politeness, and it does it before the window shuts. Free, iPhone only. Download it before you fly, so the sorting's already running when you land.
Read by the field teams and medical-affairs leads heading to Chicago who want the read before they fly.
Field notes on conference networking, follow-up timing, and what we ship next. No spam, no AI hype.
No spam. Unsubscribe anytime. Replies go to support@sailquery.com.